Glenmark Pharmaceuticals approves ₹2.50 dividend, FY26 financials at AGM
- Shareholders approved FY26 standalone and consolidated financial statements
- Final dividend of ₹2.50 per equity share declared for FY26
- Mrs. Blanche Saldanha reappointed as Non-Executive Director
- Cost auditor remuneration ratified for FY27
- All resolutions passed with majority support exceeding 95%
*this image is generated using AI for illustrative purposes only.
Glenmark Pharmaceuticals shareholders approved the company's audited standalone and consolidated financial statements for FY26, alongside a final dividend of ₹2.50 per equity share. The 48th Annual General Meeting (AGM) concluded on September 11, 2026, with all resolutions passing by requisite majorities.
The meeting, held via Video Conferencing/Other Audio Visual Means (OAVM), saw participation from 54 shareholders. Mr. Glenn Saldanha, Chairman cum Managing Director & CEO, presided over the proceedings. He outlined the company's performance in FY25-26, highlighting innovation, commercial foundation strengthening, and quality growth.
Voting Results
Shareholders voted overwhelmingly in favor of the ordinary business resolutions. The adoption of the standalone financial statements received support from 99.92% of valid votes cast. Similarly, the consolidated financial statements were approved with 95.88% support.
The declaration of the final dividend garnered near-unanimous approval, with 99.99% of votes cast in favor. Only 490 shares voted against the dividend resolution out of more than 230 million shares participating.
| Resolution | Votes For (%) | Votes Against (%) |
|---|---|---|
| Standalone Financials | 99.92% | 0.08% |
| Consolidated Financials | 95.88% | 4.12% |
| Final Dividend (₹2.50) | 99.99% | 0.00% |
| Reappointment of Director | 99.77% | 0.23% |
| Cost Auditor Remuneration | 99.99% | 0.00% |
Board Appointments and Auditors
Under special business, shareholders approved the reappointment of Mrs. Blanche Saldanha as a Non-Executive Director, liable to retire by rotation. This resolution passed with 99.77% of votes in favor.
The company also ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. This ordinary resolution received 99.99% support from voting members.
What the Numbers Show
The voting data indicates strong institutional and retail alignment on capital allocation and governance. The near-unanimous support for the dividend (99.99%) contrasts slightly with the consolidated financials approval (95.88%), where over 9.4 million shares voted against. This divergence suggests a segment of shareholders may have reservations regarding specific consolidated metrics or subsidiary performance, despite endorsing the parent entity's standalone results and payout policy.
Historical Stock Returns for Glenmark Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.17% | -1.62% | +7.46% | +8.69% | +13.53% | 0.0% |
What specific factors within the consolidated financials prompted the 4.12% dissenting vote, and how might this impact investor confidence in subsidiary performance?
How does the ₹2.50 per share final dividend compare to Glenmark's historical payout ratios, and what does this signal about future capital allocation strategies?
Given the emphasis on 'innovation' and 'commercial foundation strengthening,' what new product launches or market expansions are expected to drive revenue growth in FY27?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
